Mereo BioPharma Group plc
MREODrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How MREO's past catalysts played out
BCT197
Pulmonary Disease, Chronic Obstructive
Alvelestat oral tablet - dose 1
Alpha 1-Antitrypsin Deficiency
Etigilimab
Solid Tumor, Adult
BGS649
Hypogonadotropic Hypogonadism
Active treatment with a high dose of BGS649
Endometriosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BCT197 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Alvelestat oral tablet - dose 1 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Etigilimab | Phase 2 | Solid Tumor, Adult | - | - |
BGS649 | Phase 2 | Hypogonadotropic Hypogonadism | - | - |
Active treatment with a high dose of BGS649 | Phase 2 | Endometriosis | - | - |
Frequently asked questions
What is in Mereo BioPharma Group plc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Mereo BioPharma Group plc's (MREO) pipeline across Phase 2. Its lead program is BCT197 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mereo BioPharma Group plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Mereo BioPharma Group plc (MREO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MREO biotech catalysts?→
Add MREO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mereo BioPharma Group plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.